Relevant bibliographies by topics / Drug repurposing against COVID-19

Academic literature on the topic 'Drug repurposing against COVID-19'

Author: Grafiati
Published: 6 September 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Contents

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Drug repurposing against COVID-19.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Drug repurposing against COVID-19"

1

Mohate, Pratiksha, and Madhav D. Zade. "REVIEW ON DRUG REPURPOSING DRUG USEFUL AGAINST COVID-19." International Journal of Engineering Applied Sciences and Technology 5, no. 2 (June 30, 2020): 449–55. http://dx.doi.org/10.33564/ijeast.2020.v05i02.074.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Rodrigues, Liliana, Renata Bento Cunha, Tatiana Vassilevskaia, Miguel Viveiros, and Celso Cunha. "Drug Repurposing for COVID-19: A Review and a Novel Strategy to Identify New Targets and Potential Drug Candidates." Molecules 27, no. 9 (April 23, 2022): 2723. http://dx.doi.org/10.3390/molecules27092723.

Full text
Abstract:
In December 2019, the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19) was first identified in the province of Wuhan, China. Since then, there have been over 400 million confirmed cases and 5.8 million deaths by COVID-19 reported worldwide. The urgent need for therapies against SARS-CoV-2 led researchers to use drug repurposing approaches. This strategy allows the reduction in risks, time, and costs associated with drug development. In many cases, a repurposed drug can enter directly to preclinical testing and clinical trials, thus accelerating the whole drug discovery process. In this work, we will give a general overview of the main developments in COVID-19 treatment, focusing on the contribution of the drug repurposing paradigm to find effective drugs against this disease. Finally, we will present our findings using a new drug repurposing strategy that identified 11 compounds that may be potentially effective against COVID-19. To our knowledge, seven of these drugs have never been tested against SARS-CoV-2 and are potential candidates for in vitro and in vivo studies to evaluate their effectiveness in COVID-19 treatment.
APA, Harvard, Vancouver, ISO, and other styles
3

Khataniar, Ankita, Upasana Pathak, Sanchaita Rajkhowa, and Anupam Nath Jha. "A Comprehensive Review of Drug Repurposing Strategies against Known Drug Targets of COVID-19." COVID 2, no. 2 (January 26, 2022): 148–67. http://dx.doi.org/10.3390/covid2020011.

Full text
Abstract:
Drug repurposing is a more inexpensive and shorter approach than the traditional drug discovery and development process. The concept of identifying a potent molecule from a library of pre-existing molecules or an already approved drug has become a go-to tactic to accelerate the identification of drugs that can prevent COVID-19. This seemingly uncontrollable disease is caused by SARS-CoV-2. It is a novel virus of the Betacoronavirus genus, exhibiting similarities to the previously reported SAR-CoV genome structure and viral pathogenesis. The emergence of SARS-CoV-2 and the rapid outbreak of COVID-19 have resulted in a global pandemic. Researchers are hard-pressed to develop new drugs for total containment of the disease, thus making the cost-effective drug repurposing a much more feasible approach. Therefore, the current review attempts to collate both the experimental and computational drug repurposing strategies that have been utilized against significant drug targets of SARS-CoV-2. Along with the strategies, the available druggable targets shall also be discussed. However, the occurrence of frequent recombination of the viral genome and time-bound primary analysis, resulting in insignificant data, are two major challenges that drug repurposing still faces.
APA, Harvard, Vancouver, ISO, and other styles
4

Puccetti, Matteo, Claudio Costantini, Maurizio Ricci, and Stefano Giovagnoli. "Tackling Immune Pathogenesis of COVID-19 through Molecular Pharmaceutics." Pharmaceutics 13, no. 4 (April 5, 2021): 494. http://dx.doi.org/10.3390/pharmaceutics13040494.

Full text
Abstract:
An increasing number of clinical studies worldwide are investigating the repurposing of antiviral, immune-modulatory, and anti-inflammatory agents to face the coronavirus disease-19 (COVID-19) pandemic. Nevertheless, few effective therapies exist to prevent or treat COVID-19, which demands increased drug discovery and repurposing efforts. In fact, many currently tested drugs show unknown efficacy and unpredictable drug interactions, such that interventions are needed to guarantee access to effective and safe medicines. Anti-inflammatory therapy has proven to be effective in preventing further injury in COVID-19 patients, but the benefit comes at a cost, as targeting inflammatory pathways can imply an increased risk of infection. Thus, optimization of the risk/benefit ratio is required in the anti-inflammatory strategy against COVID-19, which accounts for drug formulations and delivery towards regionalization and personalization of treatment approaches. In this perspective, we discuss how better knowledge of endogenous immunomodulatory pathways may optimize the clinical use of novel and repurposed drugs against COVID-19 in inpatient, outpatient, and home settings through innovative drug discovery, appropriate drug delivery systems and dedicated molecular pharmaceutics.
APA, Harvard, Vancouver, ISO, and other styles
5

Wahedi, Hussain Mustatab, and Deeba Amraiz. "Repurposing of Antiviral Drugs for Covid-19 Therapy." Life and Science 1, supplement (December 23, 2020): 10. http://dx.doi.org/10.37185/lns.1.1.151.

Full text
Abstract:
Coronavirus disease (COVID-19) caused by severe acute respiratory syndrome-associated coronavirus 2 (SARS- CoV-2) is one of the biggest health challenges across the globe ever since its eruption in late 2019. Novelty, contagiousness, and lethality of the virus demand the expedited production of potential therapeutic agents and strategies against it. Since no COVID-19 specific drug is available yet, it persists a crucial challenge to determine what therapeutic strategies should be adopted for the treatment of coronavirus patients. Until there is any specific drug for COVID-19, repurposing of the existing FDA-approved drugs is the most suitable approach to treat the severely ill patients of COVID-19. This review will summarize the existing antiviral drugs being repurposed and probed for their potential as effective anti-COVID-19 drugs all over the world.
APA, Harvard, Vancouver, ISO, and other styles
6

Kumari, Priyanka, Bikram Pradhan, Maria Koromina, George P. Patrinos, and Kristel Van Steen. "Discovery of new drug indications for COVID-19: A drug repurposing approach." PLOS ONE 17, no. 5 (May 24, 2022): e0267095. http://dx.doi.org/10.1371/journal.pone.0267095.

Full text
Abstract:
Motivation The outbreak of coronavirus health issues caused by COVID-19(SARS-CoV-2) creates a global threat to public health. Therefore, there is a need for effective remedial measures using existing and approved therapies with proven safety measures has several advantages. Dexamethasone (Pubchem ID: CID0000005743), baricitinib(Pubchem ID: CID44205240), remdesivir (PubchemID: CID121304016) are three generic drugs that have demonstrated in-vitro high antiviral activity against SARS-CoV-2. The present study aims to widen the search and explore the anti-SARS-CoV-2 properties of these potential drugs while looking for new drug indications with optimised benefits via in-silico research. Method Here, we designed a unique drug-similarity model to repurpose existing drugs against SARS-CoV-2, using the anti-Covid properties of dexamethasone, baricitinib, and remdesivir as references. Known chemical-chemical interactions of reference drugs help extract interactive compounds withimprovedanti-SARS-CoV-2 properties. Here, we calculated the likelihood of these drug compounds treating SARS-CoV-2 related symptoms using chemical-protein interactions between the interactive compounds of the reference drugs and SARS-CoV-2 target genes. In particular, we adopted a two-tier clustering approach to generate a drug similarity model for the final selection of potential anti-SARS-CoV-2 drug molecules. Tier-1 clustering was based on t-Distributed Stochastic Neighbor Embedding (t-SNE) and aimed to filter and discard outlier drugs. The tier-2 analysis incorporated two cluster analyses performed in parallel using Ordering Points To Identify the Clustering Structure (OPTICS) and Hierarchical Agglomerative Clustering (HAC). As a result, itidentified clusters of drugs with similar actions. In addition, we carried out a docking study for in-silico validation of top candidate drugs. Result Our drug similarity model highlighted ten drugs, including reference drugs that can act as potential therapeutics against SARS-CoV-2. The docking results suggested that doxorubicin showed the least binding energy compared to reference drugs. Their practical utility as anti-SARS-CoV-2 drugs, either individually or in combination, warrants further investigation.
APA, Harvard, Vancouver, ISO, and other styles
7

Kumari, Kanchan, and Sandip K Mishra. "Artemisinin and its Derivatives as Repurposing Drug against COVID-19." Acta Scientific Cancer Biology 4, no. 7 (June 22, 2020): 21–23. http://dx.doi.org/10.31080/ascb.2020.04.0237.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Parvathaneni, Vineela, and Vivek Gupta. "Utilizing drug repurposing against COVID-19 – Efficacy, limitations, and challenges." Life Sciences 259 (October 2020): 118275. http://dx.doi.org/10.1016/j.lfs.2020.118275.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Ciliberto, Gennaro, and Luca Cardone. "Boosting the arsenal against COVID-19 through computational drug repurposing." Drug Discovery Today 25, no. 6 (June 2020): 946–48. http://dx.doi.org/10.1016/j.drudis.2020.04.005.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Kolitz, Sarah, Jason Kim, Jenny Zhang, Yoonjeong Cha, Sailaja Battula, Rebecca Kusko, Rajaraman Krishnan, Benjamin Zeskind, and Howard Kaufman. "477 Deep learning to drive COVID-19 rapid drug repurposing." Journal for ImmunoTherapy of Cancer 8, Suppl 3 (November 2020): A509. http://dx.doi.org/10.1136/jitc-2020-sitc2020.0477.

Full text
Abstract:
BackgroundCOVID-19 is a global public health crisis with no effective therapeutic strategies or vaccines available. The disease is caused by the SARS-CoV-2 virus, a novel coronavirus that enters cells through the ACE2 receptor. To rapidly identify existing drugs that might preferentially bind to the ACE2 receptor we sought to use an artificial intelligence platform to evaluate ~3,000 known drugs in the FDA approved drug library (Selleckchem).MethodsFluency is a quantitative structure–activity relationship (QSAR) deep learning-based platform that evaluates small molecule drug binding to protein targets. All drug structures from the FDA approved library were evaluated for binding to the ACE2 receptor and re-filtered for preferential ACE2 vs. ACE1 receptor binding. Top hits were evaluated for specificity by predicting binding across the human proteome and filtered by evaluating rankings from each of two models along with average ranks and combined scores from both models. The drugs were then evaluated for classification, potential availability and prioritized for in vitro validation. Selected compounds were screened using a high-throughput SARS-CoV-2 cell-based assay as described previously (Jonsson et al. J Biomol Screen 2007 12: 33. DOI: 10.1177/1087057106296688). Plates are quality-controlled in each run using Z score and CV statistics. Positive controls consisting of cells only and negative controls consisting of virus were used to normalize the data. Individual drugs are added to each plate at a single dose with at least four doses tested. For titer reduction assays, VeroE6 cells are infected with virus at MOI of 0.1 for one hour to promote adsorption. After two days, the supernatant is harvested and the amount of virus in each well is measured using TCID50 or plaque assay.ResultsWe identified 25 top drugs that were predicted to bind to ACE2 receptors and could theoretically block SARS-CoV-2 cell entry. Of these drugs, we prioritized 12 drugs for validation covering multiple pharmacologic classes and after assessing drug availability (table 1). They included an ALK/EGFR inhibitor, JAK inhibitor, two electrolyte channel inhibitors, \an antibiotic, and several anti-viral drugs, ACE inhibitors and anticoagulants. Validation studies are in progress and viral inhibition and titer reduction data will be presented.ConclusionsOur data show that machine learning platforms can be used to rapidly identify existing drugs that may have activity against SARS-CoV-2 infection. This hybrid computational and experimental approach enables rapid discovery of drugs for clinical testing against COVID-19 and other emerging human diseases.AcknowledgementsWe would like to thank Dr. Colleen Jonsson and Dr. Jeremy Smith at Oak Ridge National Laboratories and the University of Tennessee Regional Biocontainment Laboratory for assistance with in vitro validation studies.Trial RegistrationN/AEthics ApprovalN/AConsentN.A
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Drug repurposing against COVID-19"

1

Brás, Ana Luzia Alves. "Relatórios de Estágio e Monografia intitulada “Drug Repurposing: Uma oportunidade para as empresas farmacêuticas nacionais”." Master's thesis, 2020. http://hdl.handle.net/10316/93040.

Full text
Abstract:
Relatório de Estágio do Mestrado Integrado em Ciências Farmacêuticas apresentado à Faculdade de Farmácia
Por drug repurposing (DR) entende-se o recurso a fármacos já aprovados para determinada patologia, com o intuito de identificar novas propriedades, direcionando-os para uma nova indicação terapêutica. Pela existência de dados de segurança, esta abordagem beneficia de custos mais reduzidos e de intervalos de tempo mais curtos. Desta forma, combinam-se medicamentos para criar um tratamento com eficácia superior, comparativamente, ao seu uso em monoterapia, ou investigam-se novos mecanismos de ação. Desta investigação surgem novas indicações terapêuticas, normalmente, na mesma classe farmacológica.Com o intuito de avaliar a hipótese do DR poder ser uma oportunidade para as empresas farmacêuticas nacionais, analisou-se o benefício de colaborações entre organizações, identificou-se uma área emergente e ponderou-se as suas vantagens e desvantagens, bem como os passos futuros a executar.Em 2020, a doença que é provocada pela infeção por coronavírus (COVID-19) tornou-se uma ameaça à saúde pública, a nível mundial. Por este motivo, emergiu a necessidade de uma vacina e / ou um medicamento para que a transmissão da doença estagnasse e para combater a mortalidade que lhe está associada. Nas circunstâncias atuais, o DR surge como alternativa para avançar de forma fugaz na procura por uma solução para travar esta pandemia, ao contrário do que aconteceu com outras antecedentes. Esta ferramenta tem custos reduzidos associados, pelo que pode ser considerada uma oportunidade de investimento por parte das empresas farmacêuticas nacionais.De notar que apesar da existência de inúmeros benefícios, ainda se encontram barreiras por ultrapassar, tais como ampliar as propostas de financiamento, simplificar a conjetura regulamentar e identificar métodos que minimizem erros fortuitos.
Drug repurposing (DR) means the use of drugs already approved for a given pathology, to identify new properties, directing them to a new therapeutic indication. Due to the existence of safety data, this approach benefits from lower costs and shorter time intervals. In this way, drugs are combined to create a treatment with superior efficacy, compared to its use in monotherapy, or new mechanisms of action are investigated. From this research new therapeutic indications usually arise in the same pharmacological class.In order to evaluate the hypothesis that DR may be an opportunity for national pharmaceutical companies, the benefit of collaborations between organizations was analysed, an emerging area was identified and its advantages and disadvantages were pondered, as well as the future steps to be taken.In 2020, the disease caused by coronavirus infection (COVID-19) became a threat to public health worldwide. For this reason, the need for a vaccine and/or a drug has emerged to stagnate the transmission of the disease and to combat the mortality associated with it. In the current circumstances, DR emerges as an alternative to move forward fleetingly in the search for a solution to stop this pandemic, unlike what happened with other precedents. This tool has low associated costs and can therefore be considered an investment opportunity by national pharmaceutical companies.It should be noted that despite the existence of numerous benefits, there are still obstacles to be overcome, such as extending funding proposals, simplifying the regulatory conjecture, and identifying methods to minimise fortuitous errors.
APA, Harvard, Vancouver, ISO, and other styles

Books on the topic "Drug repurposing against COVID-19"

1

Drago, Filippo, and Rafael Maldonado, eds. Drug Repurposing for COVID-19 Therapy. Frontiers Media SA, 2021. http://dx.doi.org/10.3389/978-2-88971-485-8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Drago, Filippo, and Rafael Maldonado, eds. Drug Repurposing for COVID-19 Therapy. Frontiers Media SA, 2021. http://dx.doi.org/10.3389/978-2-88971-485-8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Sekeres, Mikkael A. Drugs and the FDA. The MIT Press, 2022. http://dx.doi.org/10.7551/mitpress/13620.001.0001.

Full text
Abstract:
How the FDA was shaped by public health crises and patient advocacy, told against a background of the contentious hearings on the breast cancer drug Avastin. Food and Drug Administration approval for COVID-19 vaccines and the controversial Alzheimer's drug Aduhelm made headlines, but few of us know much about how the agency does its work. Why is the FDA the ultimate US authority on a drug's safety and efficacy? In Drugs and the FDA, Mikkael Sekeres—a leading oncologist and former chair of the FDA's cancer drug advisory committee—tells the story of how the FDA became the most trusted regulatory agency in the world. It took a series of tragedies and health crises, as well as patient advocacy, for the government to take responsibility for ensuring the efficacy and safety of drugs and medical devices. Before the FDA existed, drug makers could hawk any potion, claim treatment of any ailment, and make any promise on a label. But, throughout the twentieth century, the government was forced to take increasing action when children were poisoned by contaminated diphtheria and smallpox vaccines, an early antibiotic contained antifreeze, a drug prescribed for morning sickness in pregnancy caused babies to be born disfigured, and access to AIDS drugs was limited to a few clinical trials while thousands died. Sekeres describes all these events against the backdrop of the contentious 2011 hearings on the breast cancer drug Avastin, in which he participated as a panel member. The Avastin hearings, he says, put to the test a century of the FDA's evolution, demonstrating how its system of checks and balances works—or doesn't work.
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Drug repurposing against COVID-19"

1

Yadav, Monu, Pratibha Dhakla, Rahul Rawat, Mini Dahiya, and Anil Kumar. "Therapeutic Repurposing Approach: New Opportunity for Developing Drugs Against COVID-19." In Drug Repurposing for Emerging Infectious Diseases and Cancer, 543–68. Singapore: Springer Nature Singapore, 2023. http://dx.doi.org/10.1007/978-981-19-5399-6_24.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Dwivedi, Shailendra, Aakanksha Rawat, Amit Ranjan, Ruchika Agrawal, Radhieka Misra, Sunil Kumar Gupta, Surekha Kishore, and Sanjeev Misra. "Drug Repurposing and Novel Antiviral Drugs for COVID-19 Management." In COVID-19, 74–95. Boca Raton: CRC Press, 2022. http://dx.doi.org/10.1201/9781003190394-7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Truong, Anh T. L., Agata Blasiak, Mathias Egermark, and Dean Ho. "AI for Drug Repurposing in the Pandemic Response." In Artificial Intelligence in Covid-19, 59–84. Cham: Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-031-08506-2_3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Abdelhady, Aya Salama, Yaseen A. M. M. ElShaier, Mohamed S. Refaey, Ahmed Elsyaed Elmasry, and Aboul Ella Hassanien. "Intelligent Drug Descriptors Analysis: Toward COVID-19 Drug Repurposing." In Studies in Computational Intelligence, 173–91. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-91103-4_10.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Tripathi, Manish Kumar, Sujata Sharma, Tej P. Singh, A. S. Ethayathulla, and Punit Kaur. "Computational Intelligence in Drug Repurposing for COVID-19." In Studies in Computational Intelligence, 273–94. Singapore: Springer Singapore, 2020. http://dx.doi.org/10.1007/978-981-15-8534-0_14.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Boutorh, Aicha, Kaouter Marref, and Naamat Ellah Dehiri. "Graph Representation Learning for Covid-19 Drug Repurposing." In Advances in Computing Systems and Applications, 61–72. Cham: Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-031-12097-8_6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Al-Harrasi, Ahmed, Saurabh Bhatia, Tanvir Kabir, Tapan Behl, and Deepak Kaushik. "Role of Drug Repurposing and Natural Products." In Role of Essential Oils in the Management of COVID-19, 61–97. Boca Raton: CRC Press, 2022. http://dx.doi.org/10.1201/9781003175933-6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

O'Reilly, Sophie, Matthew Angeliadis, Ross Murtagh, and Virginie W. Gautier. "Drug repurposing and other strategies for rapid coronavirus antiviral development: lessons from the early stage of the COVID-19 pandemic." In COVID-19, 39–68. Sheffield, United Kingdom: European Respiratory Society, 2021. http://dx.doi.org/10.1183/2312508x.10024020.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Chopra, Simran, Aditya Dahiya, Ashrit Nair, Navneet Sharma, and Rakesh Kumar Sharma. "2-Deoxy-d-Glucose: A Repurposed Drug for COVID-19 Treatment." In Drug Repurposing for Emerging Infectious Diseases and Cancer, 479–500. Singapore: Springer Nature Singapore, 2023. http://dx.doi.org/10.1007/978-981-19-5399-6_20.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Verma, Rohit, Shivani Raj, Umang Berry, C. T. Ranjith-Kumar, and Milan Surjit. "Drug Repurposing for COVID-19 Therapy: Pipeline, Current Status and Challenges." In Drug Repurposing for Emerging Infectious Diseases and Cancer, 451–78. Singapore: Springer Nature Singapore, 2023. http://dx.doi.org/10.1007/978-981-19-5399-6_19.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Drug repurposing against COVID-19"

1

Bastikar, Alpana, Virupaksha Bastikar, Santosh Chhajed, and PramodKumar Gupta. "Targeting SARS-CoV2 Main Protease using HTVS and simulation analysis: A drug repurposing approach against COVID-19." In 6th International Electronic Conference on Medicinal Chemistry. Basel, Switzerland: MDPI, 2020. http://dx.doi.org/10.3390/ecmc2020-07803.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Adnan, Md, Md Nazim Uddin Chy, Md Riad Chowdhury, and A. T. M. Mostafa Kamal. "<em>In silico</em> virtual screening of known drugs against SARS-CoV-2 3CL protease: A drug repurposing approach for COVID-19." In 6th International Electronic Conference on Medicinal Chemistry. Basel, Switzerland: MDPI, 2020. http://dx.doi.org/10.3390/ecmc2020-07363.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

"Drug repurposing for COVID-19 therapy: challenges and opportunities." In Bioinformatics of Genome Regulation and Structure/Systems Biology (BGRS/SB-2022) :. Institute of Cytology and Genetics, the Siberian Branch of the Russian Academy of Sciences, 2022. http://dx.doi.org/10.18699/sbb-2022-198.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Aqeel, Imra, Sadia Zafar, Muhammad Bilal, and Abdul Majid. "Drug Repurposing for CoVID-19 Spike Protein through Molecular Docking." In 2022 International Conference on Recent Advances in Electrical Engineering & Computer Sciences (RAEE & CS). IEEE, 2022. http://dx.doi.org/10.1109/raeecs56511.2022.9954482.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Wang, Qingyun, Manling Li, Xuan Wang, Nikolaus Parulian, Guangxing Han, Jiawei Ma, Jingxuan Tu, et al. "COVID-19 Literature Knowledge Graph Construction and Drug Repurposing Report Generation." In Proceedings of the 2021 Conference of the North American Chapter of the Association for Computational Linguistics: Human Language Technologies: Demonstrations. Stroudsburg, PA, USA: Association for Computational Linguistics, 2021. http://dx.doi.org/10.18653/v1/2021.naacl-demos.8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Pacl, H. T., J. L. Tipper, G. D. Holder, R. R. Sevalkar, S. Nadeem, K. C. Chinta, A. Crouse, A. J. C. Steyn, M. Might, and K. S. Harrod. "Identification and Assessment of FDA-Approved Drugs for Repurposing as Single and Combination Therapies Against SARS-CoV-2 Infection." In American Thoracic Society 2021 International Conference, May 14-19, 2021 - San Diego, CA. American Thoracic Society, 2021. http://dx.doi.org/10.1164/ajrccm-conference.2021.203.1_meetingabstracts.a3767.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Rabbani, Naila, Paul John Thornalley, Maryam Al-Motawa, and Mingzhan Xue. "Vulnerabilities of the SARS-Cov-2 Virus to Proteotoxicity – Opportunity for Repurposed Chemotherapy of COVID-19 Infection." In Qatar University Annual Research Forum & Exhibition. Qatar University Press, 2020. http://dx.doi.org/10.29117/quarfe.2020.0291.

Full text
Abstract:
The global pandemic of COVID-19 disease caused by infection with the SARS-CoV-2 Coronavirus, has produced an urgent requirement and search for improved treatments whilst effective vaccines are developed. A strategy for improved drug therapy is to increase levels of endogenous reactive metabolites for selective toxicity to SARS-CoV-2 by preferential damage to the viral proteome. Key reactive metabolites producing major quantitative damage to the proteome in physiological systems are: Reactive oxygen species (ROS) and the reactive glycating agent methylglyoxal (MG); cysteine residues and arginine residues are their most susceptible targets, respectively. From sequenced-based prediction of the SARS-CoV-2 proteome, we found 0.8-fold enrichment or depletion of cysteine residues in functional domains of the viral proteome; whereas there was a 4.6-fold enrichment of arginine residues, suggesting SARS-CoV-2 is resistant to oxidative agents and sensitive to MG. We examined activated arginine residues in functional domain with predicted low pKa by neighboring group interaction in the SARS-CoV-2. We found 25 such arginine residues, including 2 in the spike protein and 10 in the nucleoprotein. These sites were partially conserved in related coronaviridae: SARS-COV and MERS. We also screened and identified drugs, which increase cellular MG concentration to virucidal levels and found two antitumor drugs with historical antiviral activity, doxorubicin and paclitaxel were the best candidate for repurposing. Our findings provide evidence of potential vulnerability of SARS-CoV2 to inactivation by MG and a scientific rationale for repurposing of doxorubicin and paclitaxel for treatment of COVID-19 disease, providing efficacy and adequate therapeutic index may be established.
APA, Harvard, Vancouver, ISO, and other styles
8

Chowdhury, Md Riad, and Sadia Akter. "&lt;em&gt;In silico &lt;/em&gt;screening of therapeutic agents for COVID-19: A drug repurposing approach." In 7th International Electronic Conference on Medicinal Chemistry. Basel, Switzerland: MDPI, 2021. http://dx.doi.org/10.3390/ecmc2021-11359.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Svitich, Oxana A., N. D. Abramova, I. V. Bisheva, E. A. Khromova, S. A. Skhodova, N. O. Kryukova, I. A. Baranova, et al. "The level of sIgA in nasal secretions and the incidence of complications in hospitalized patients with COVID-19 against an immunotropic drug." In ERS Lung Science Conference 2022 abstracts. European Respiratory Society, 2022. http://dx.doi.org/10.1183/23120541.lsc-2022.258.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Cunha, Vinícius Gonçalves Portilho, Alda Maria de Sousa Mendonça, Amanda Selvátici dos Santos Dias, and Ketteny de Lima Rodrigues. "Pediatric onset multiple sclerosis: defying disability – a case report." In XIV Congresso Paulista de Neurologia. Zeppelini Editorial e Comunicação, 2023. http://dx.doi.org/10.5327/1516-3180.141s1.661.

Full text
Abstract:
Introduction: Multiple sclerosis (MS) is the main demyelinating disturbance of the central nervous system in childhood and, compared to adulthood, the disease presents in a more inflammatory way and with greater probability of younger disability if not well managed in adequate time. Objectives: Case report of a patient with pediatric onset multiple sclerosis (POMS) and high lesions burden in need of high efficacy medications in early time. Methods: The present case report was based on data collected through literature review and medical records. Results: We found the case of a 12-year-old girl presenting with monoparesis of right leg and being first diagnosed with acute disseminated encephalomyelitis due to lesions with a demyelinating character in a skull magnetic resonance (MRI) in January 2022 after COVID-19 vaccination. After six months, she presented with diplopia and ataxia, besides worsening of radiological pattern of the previous lesions and evidence of spinal involvement, being submitted to therapy with methylprednisolone. Further, the diagnosis of POMS was stablished due to oligoclonal bands in cerebrospinal fluid and negativity to serum anti aquaporin 4 and serum antibody against myelin oligodendrocyte glycoprotein; treatment with natalizumab was started. After four months, she presented with worsening of previous neurological deficits and progression of disease was seen in a new skull and neuroaxis MRI, being submitted to a new cycle of methylprednisolone and five sessions of plasmapheresis. After these therapies, she went home with an expanded disability status scale of 4 and rituximab was the chosen drug to continue treatment according to literature and the neurological state. Conclusion: Early intervention in pediatric onset multiple sclerosis is necessary to avoid the maximum of future disability and high inflammatory level frequently demands high efficacy therapies to control the disease.
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Drug repurposing against COVID-19' for particular source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography